poison ligand-targeted (LTTs) are artificial molecules that consist of a targeting component associated with the toxins that induce cell death after binding targets LTT. targeting bispecific allows for the simultaneous targeting of two receptors. In this review, we mostly focus on epidermal growth factor receptor (EGFR) as a target. We discuss the development and testing of LTT bispecific targeting EGFR and urokinase-type plasminogen activator receptor (Upar) as two attractive targets involved in tumor growth and in the regulation of the tumor microvasculature in solid tumors. In vitro and mouse xenograft studies have demonstrated that EGFR-targeted bispecific angiotoxin (eBAT) effective against human solid tumors. Studies have shown that eBAT dog is safe and effective against canine hemangiosarcoma, which are physiologically similar to human angiosarcoma.
Finding the right dose strategy and sequencing eBAT administration, in combination with other therapies, among the factors important for the future direction. Together, the data suggest that stem cells eBAT cancer targets, may have a role in inhibiting tumor blood vessels, human, and bispecific conformations that may have a role in reducing the toxicity of the oncologic comparative trials in dogs. The urokinase plasminogen activator and its receptor (uPA / Upar) is a biomarker for metastasis, particularly in triple-negative breast cancer.
We set up an anti-mitotic N-alkylisatin (N-AI) -loaded liposomes functionalized with uPA / Upar targeting ligand, plasminogen activator inhibitor type 2 (PAI-2 / SerpinB2), and rated liposome uptake in vitro and in vivo. receptor dependent uptake of liposome-functionalized PAI-2 was significantly higher in the uPA / Upar overexpressing MDA-MB-231 breast cancer cells is relatively low Upar / Upar expressing MCF-7 breast cancer cells. Furthermore, N-AI cytotoxicity enhanced by receptor-dependent manner.
In vivo, PAI-2 N-AI liposomes have a plasma half-life of 5.82 h and showed increased accumulation at the primary tumor site in the MDA-MB-231 BALB / c-Fox1nu / Ausb mouse orthotopic xenograft model, relative to non-functionalized liposome , up to 6 hours post injection. These findings support the further development of the N-AI-loaded liposomes PAI-2-enabled for breast cancer uPA / Upar-positive, especially against triple-negative breast cancer, the prognosis is poor and treatment is limited.
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer
Soluble urokinase plasminogen activator receptor as a prognostic biomarker for long-term acute coronary syndrome
Objective: The aim of our study was to analyze the long-term prognostic value soluble urokinase plasminogen activator receptor (Supar) in the setting of acute coronary syndromes (ACS) .Methods: We included 340 patients with ACS undergoing coronary angiography and plasma concentrations were measured Supar. Patients were classified into Supar low concentrations (<2.6 ng / mL) and high Supar concentration (≥2.6 ng / mL) and long-term events are evaluated.
Supar rated prognostic value beyond the clinical model that included age, GRACE score, estimated glomerular filtration rate, cardiac troponin-I peak and left ventricular ejection fraction <40% .Results: Higher concentrations Supar associated with an increased prevalence of cardiovascular risk factors.
Description: A competitive ELISA for quantitative measurement of Human Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
Description: Quantitative sandwich ELISA for measuring Human Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: A competitive ELISA for quantitative measurement of Canine Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Urokinase . This antibody is tested and proven to work in the following applications:
Description: A competitive ELISA for quantitative measurement of Human Urokinase plasminogen activator in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase plasminogen activator in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase plasminogen activator in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
Description: PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
Description: Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Plasminogen Activator, Urokinase (uPA) in Plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA)CLIA Kit
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Plasminogen Activator, Urokinase (uPA) in Plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA)CLIA Kit
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Plasminogen Activator, Urokinase (uPA) in Plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA)CLIA Kit
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Plasminogen Activator, Urokinase (uPA) in Plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA) CLIA Kit
Description: Double-antibody Sandwich chemiluminescent immunoassay for detection of Human Plasminogen Activator, Urokinase (uPA)Plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Description: A sandwich quantitative ELISA assay kit for detection of Human Plasminogen Activator, Urokinase (uPA) in samples from plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Human Plasminogen Activator, Urokinase (uPA) ELISA Kit
Description: A sandwich quantitative ELISA assay kit for detection of Human Plasminogen Activator, Urokinase (uPA) in samples from plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Human urokinase plasminogen activator, uPA ELISA kit
Description: Quantitative sandwich ELISA kit for measuring Human urokinase plasminogen activator, uPA in samples from serum, plasma, tissue homogenates, urine. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human urokinase plasminogen activator, uPA ELISA kit
Description: Quantitative sandwich ELISA kit for measuring Human urokinase plasminogen activator, uPA in samples from serum, plasma, tissue homogenates, urine. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human Plasminogen Activator, Urokinase ELISA Kit (uPA)
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Plasminogen Activator, Urokinase (uPA) in plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA) ELISA Kit
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Plasminogen Activator, Urokinase (uPA) in plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA) ELISA Kit
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Plasminogen Activator, Urokinase (uPA) in plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA) ELISA Kit
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Plasminogen Activator, Urokinase (uPA) in plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Human Plasminogen Activator, Urokinase (uPA) ELISA Kit
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Plasminogen Activator, Urokinase (uPA) in samples from plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids with no significant corss-reactivity with analogues from other species.
Human urokinase plasminogen activator,uPA ELISA kit
Description: A competitive ELISA for quantitative measurement of Guinea pig Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Human Urokinase (uPA) AssayLite Antibody (FITC Conjugate)
Description: Quantitative sandwich ELISA for measuring Rat Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: For quantitative determination of urokinase activity determination in biological samples. Key Features: Safe. Non-radioactive assay. Fast. Assay is completed within a 15 minute reaction time. Homogeneous "mix-incubate-measure" type assay. Can be readily automated to assay thousands of samples per day. Method: FL380/450 nm; Samples: Biological Samples (e.g. Urine and serum). Species: All. Procedure: assay takes 15min. Size: 100 tests. Detection Limit: 0.04 U/L.
ELISA kit for Human uPA (Plasminogen Activator, Urokinase)
Description: A sandwich ELISA kit for detection of Plasminogen Activator, Urokinase from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
ELISA kit for Human Urokinase plasminogen activator (UPA)
Description: Quantitative sandwich ELISA for measuring Human Urokinase plasminogen activator (UPA) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Urokinase plasminogen activator (UPA)
Description: Quantitative sandwich ELISA for measuring Human Urokinase plasminogen activator (UPA) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human Urokinase plasminogen activator (UPA)
Description: Quantitative sandwich ELISA for measuring Human Urokinase plasminogen activator (UPA) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
ELISA kit for Human urokinase plasminogen activator,uPA
Description: Enzyme-linked immunosorbent assay kit for quantification of Human urokinase plasminogen activator,uPA in samples from serum, plasma, tissue homogenates and other biological fluids.
Recombinant Human Urokinase/ PLAU Protein, His, E.coli-1mg
Description: Recombinant Human Urokinase plasminogen activator surface receptor(PLAUR) expressed in E.coli
×
After multivariate adjustment, Supar ≥2.6 ng / mL were independently associated with an increased risk of all-cause mortality (HR 2.3; 95% CI 1.2 to 4.4; p = 0.017), major adverse cardiovascular events (MACE) ( HR 1.7; 95% CI 1.1 to 2.5; p = 0.020) and heart failure (HR 4.1; 95% CI 1.3 to 12.6; p = 0.015), but not with myocardial infarction , For long-term all-cause mortality significant increase of reclassification and discrimination Supar look after addition to the clinical model.
No Comment